- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07629479
Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH (EP-BTUEP)
Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Benign prostatic hyperplasia is a common cause of lower urinary tract symptoms in aging men. Surgical treatment is indicated when medical therapy fails or when symptoms remain bothersome. Bipolar transurethral enucleation of the prostate is an established endoscopic surgical technique for benign prostatic obstruction, but standard endoscopic prostate surgery may be associated with loss of antegrade ejaculation.
This study will evaluate whether an ejaculation-preserving modification of bipolar transurethral enucleation of the prostate can preserve ejaculatory function while maintaining effective relief of lower urinary tract symptoms. The ejaculation-preserving technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum. The control group will undergo standard bipolar transurethral enucleation of the prostate.
Eligible sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment will be randomized in a 1:1 ratio to ejaculation-preserving B-TUEP or standard B-TUEP. Sexual and urinary outcomes will be assessed using validated questionnaires and objective urinary parameters. Follow-up assessments will include ejaculatory function, erectile function, International Prostate Symptom Score, post-void residual urine, uroflowmetry, perioperative complications, and need for retreatment.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hany F Badawy, MD
- Número de teléfono: +201149525028
- Correo electrónico: HANYFATHY86@GMAIL.COM
Ubicaciones de estudio
-
-
Beni Suweif Governorate
-
Banī Suwayf, Beni Suweif Governorate, Egipto
- Reclutamiento
- Department of Urology- Beni-Suef University Hospitals
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.
- Sexually active patients with a continuous relationship with the same partner.
- International Prostate Symptom Score of 8 or greater.
- Transrectal ultrasound-estimated prostate size between 40 and 100 cc.
- Eligible for bipolar transurethral enucleation of the prostate.
- Ability to complete the required sexual and urinary function questionnaires.
- Ability to provide written informed consent.
Exclusion Criteria:
- Preoperative sexual dysfunction.
- Preoperative ejaculatory dysfunction.
- Diagnosis or suspicion of prostate cancer.
- Neurological disorders affecting lower urinary tract or sexual function.
- Detrusor hypocontractility.
- Catheter-dependent patients.
- Patients with bladder stones.
- Inability or refusal to provide informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Ejaculation-Preserving B-TUEP
Participants assigned to this arm will undergo ejaculation-preserving bipolar transurethral enucleation of the prostate.
The technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
Ejaculation-preserving bipolar transurethral enucleation of the prostate will be performed with preservation of the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
|
Comparador activo: Standard B-TUEP
Participants assigned to this arm will undergo standard bipolar transurethral enucleation of the prostate without the ejaculation-preserving modifications used in the experimental arm.
|
Standard bipolar transurethral enucleation of the prostate will be performed according to the conventional surgical technique without preservation of the paracollicular tissue and the area approximately 1 cm proximal to the verumontanum.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Function Score From Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months postoperatively
|
Ejaculatory function will be assessed using the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form function score.
The function score is based on three ejaculatory function items assessing ejaculation frequency, ejaculation force, and ejaculation volume.
The total function score ranges from 1 to 15, with higher scores indicating better ejaculatory function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
A smaller decrease or a positive change indicates better preservation of ejaculatory function.
|
Baseline and 6 months postoperatively
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Bother Score at 6 Months
Periodo de tiempo: 6 months postoperatively
|
Ejaculatory bother will be assessed using the bother item of the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form.
The bother score ranges from 0 to 5, with higher scores indicating greater bother related to ejaculatory dysfunction.
|
6 months postoperatively
|
|
Preservation of Antegrade Ejaculation at 6 Months
Periodo de tiempo: 6 months postoperatively
|
The proportion of participants with preserved antegrade ejaculation at 6 months after surgery will be compared between the ejaculation-preserving B-TUEP group and the standard B-TUEP group.
Preserved antegrade ejaculation will be defined as patient-reported antegrade seminal emission during orgasm after resumption of sexual activity.
Participants reporting absent ejaculation, dry ejaculation, or retrograde ejaculation will be considered not to have preserved antegrade ejaculation.
|
6 months postoperatively
|
|
Change in International Index of Erectile Function-5 Score From Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months postoperatively
|
Erectile function will be assessed using the International Index of Erectile Function-5 questionnaire.
The total score ranges from 5 to 25, with higher scores indicating better erectile function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in International Prostate Symptom Score From Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months postoperatively
|
Lower urinary tract symptoms will be assessed using the International Prostate Symptom Score.
The total score ranges from 0 to 35, with higher scores indicating more severe urinary symptoms.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in Maximum Urinary Flow Rate From Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months postoperatively
|
Maximum urinary flow rate will be measured by uroflowmetry and reported in milliliters per second.
The outcome will be calculated as the 6-month postoperative maximum urinary flow rate minus the baseline maximum urinary flow rate.
|
Baseline and 6 months postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hany F Badawy, MD, Faculty of medicine Beni-Suef University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FMBSUREC07092025EjBTUEP
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .